[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9504059A - Processo para a preparação de um solvato cristalino de um composto solvato cristalino processo para a preparação de hidrocloreto de 6-hidróxido-2-(4-hidroxifenil)-3-(4-(2-piperidinoetóxi)benzoil)benzo(B)tiofeno e o hidrocloreto obtido - Google Patents

Processo para a preparação de um solvato cristalino de um composto solvato cristalino processo para a preparação de hidrocloreto de 6-hidróxido-2-(4-hidroxifenil)-3-(4-(2-piperidinoetóxi)benzoil)benzo(B)tiofeno e o hidrocloreto obtido

Info

Publication number
BR9504059A
BR9504059A BR9504059A BR9504059A BR9504059A BR 9504059 A BR9504059 A BR 9504059A BR 9504059 A BR9504059 A BR 9504059A BR 9504059 A BR9504059 A BR 9504059A BR 9504059 A BR9504059 A BR 9504059A
Authority
BR
Brazil
Prior art keywords
preparation
crystalline solvate
hydrochloride
piperidinoethoxy
benzo
Prior art date
Application number
BR9504059A
Other languages
English (en)
Inventor
Labell Elizabeth Smith
Wayne Douglas Luke
John Mcneill Mcgill Iii
Randal Scot Miller
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9504059(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/308,325 external-priority patent/US5629425A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9504059A publication Critical patent/BR9504059A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR9504059A 1994-09-19 1995-09-18 Processo para a preparação de um solvato cristalino de um composto solvato cristalino processo para a preparação de hidrocloreto de 6-hidróxido-2-(4-hidroxifenil)-3-(4-(2-piperidinoetóxi)benzoil)benzo(B)tiofeno e o hidrocloreto obtido BR9504059A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/308,325 US5629425A (en) 1994-09-19 1994-09-19 Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US42791495A 1995-04-26 1995-04-26

Publications (1)

Publication Number Publication Date
BR9504059A true BR9504059A (pt) 1996-09-24

Family

ID=26976194

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9504060A BR9504060A (pt) 1994-09-19 1995-09-18 Composto e formulação farmacêutica
BR9504059A BR9504059A (pt) 1994-09-19 1995-09-18 Processo para a preparação de um solvato cristalino de um composto solvato cristalino processo para a preparação de hidrocloreto de 6-hidróxido-2-(4-hidroxifenil)-3-(4-(2-piperidinoetóxi)benzoil)benzo(B)tiofeno e o hidrocloreto obtido

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9504060A BR9504060A (pt) 1994-09-19 1995-09-18 Composto e formulação farmacêutica

Country Status (50)

Country Link
US (4) US6472531B1 (pt)
JP (2) JPH08193081A (pt)
KR (2) KR100367376B1 (pt)
CN (2) CN1075069C (pt)
AP (1) AP754A (pt)
AT (2) AT407988B (pt)
AU (3) AU691955B2 (pt)
BE (2) BE1009625A3 (pt)
BG (1) BG62793B1 (pt)
BR (2) BR9504060A (pt)
CA (2) CA2158400C (pt)
CH (3) CH691125A5 (pt)
CO (2) CO4410191A1 (pt)
CZ (2) CZ290343B6 (pt)
DE (3) DE19549755B4 (pt)
DK (4) DK175903B1 (pt)
EE (1) EE03386B1 (pt)
EG (1) EG23763A (pt)
ES (2) ES2109882B1 (pt)
FI (2) FI121424B (pt)
FR (2) FR2732020B1 (pt)
GB (2) GB2293382B (pt)
GE (1) GEP19991821B (pt)
GR (2) GR1002709B (pt)
HR (2) HRP950482B1 (pt)
HU (2) HU225417B1 (pt)
IE (2) IE80883B1 (pt)
IL (3) IL125283A (pt)
IS (1) IS1788B (pt)
IT (2) IT1277602B1 (pt)
LU (2) LU88660A1 (pt)
LV (2) LV11178B (pt)
MY (1) MY116371A (pt)
NL (2) NL1001196C2 (pt)
NO (2) NO313996B1 (pt)
NZ (2) NZ280027A (pt)
OA (1) OA10406A (pt)
PE (2) PE32796A1 (pt)
PL (2) PL187686B1 (pt)
PT (2) PT101770B (pt)
RO (2) RO115260B1 (pt)
RS (2) RS49578B (pt)
SE (2) SE520721C2 (pt)
SI (2) SI9500292A (pt)
SK (1) SK283502B6 (pt)
TR (1) TR199501136A2 (pt)
TW (1) TW412534B (pt)
UA (2) UA42716C2 (pt)
UY (1) UY24040A1 (pt)
WO (1) WO1996009045A1 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
CO4410191A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
US6458811B1 (en) * 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
EA001257B1 (ru) * 1996-03-26 2000-12-25 Эли Лилли Энд Компани Бензотиофены, содержащие их фармацевтические композиции и способы лечения патологических состояний с их использованием
ZA992858B (en) 1996-10-30 1999-07-29 Lilly Co Eli Methods of preventing breast cancer.
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
MXPA01011227A (es) 1999-05-04 2002-07-02 Strakan Ltd Glicosidas androgenas y su actividad androgenica.
US6921827B2 (en) * 2000-11-27 2005-07-26 Eli Lilly And Company Process for preparing 3-aryl-benzo{b} thiophenes
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1546138B1 (en) 2002-09-30 2012-01-18 A/S GEA Farmaceutisk Fabrik Raloxifene l-lactate or a hemihydrate thereof, their uses, pharmaceutical compositions and preparation processes
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2581843C (en) 2004-09-29 2012-05-15 Bayer Healthcare Ag Thermodynamically stable form of bay 43-9006 tosylate
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN101437823B (zh) 2006-05-04 2014-12-10 勃林格殷格翰国际有限公司 多晶型
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008047105A1 (en) * 2006-10-17 2008-04-24 Cipla Limited Crystalline form of benzothiophene compound and process for preparation thereof
US20080103295A1 (en) * 2006-10-25 2008-05-01 David Losan Ho Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst
US8258291B2 (en) * 2006-10-25 2012-09-04 Mamtek International Limited Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC)
DE102007032451B4 (de) 2007-07-12 2010-09-30 Icfs Gmbh Verfahren zur Herstellung von aromatischen Ketonen
US20090023799A1 (en) * 2007-07-20 2009-01-22 George Laurence CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE
EP2185559A1 (en) 2007-08-03 2010-05-19 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
CL2008003799A1 (es) * 2007-12-21 2009-12-18 Synthon Bv Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20110088613A1 (en) * 2008-06-09 2011-04-21 Massimo Ferrari Process for controlling the growth of a raloxifene hydrochloride crystal
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2448562B1 (en) 2009-07-02 2013-11-06 Synthon B.V. Raloxifene composition
EP2314581B1 (en) 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives
WO2011064352A1 (en) 2009-11-27 2011-06-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011099942A1 (en) 2010-02-09 2011-08-18 Silverstone Pharma New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
IT1403083B1 (it) * 2010-10-25 2013-10-04 Fidia Farmaceutici Nuova forma polimorfa di raloxifene cloridrato
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2731947B1 (en) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ZA201401636B (en) 2013-03-05 2014-11-26 Cipla Ltd Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN104496963A (zh) * 2014-12-02 2015-04-08 千辉药业（安徽）有限责任公司 一种盐酸雷洛昔芬的制备方法
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
KR102815172B1 (ko) * 2020-02-25 2025-05-29 엘지전자 주식회사 히트펌프 및 그 동작방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869485A (en) * 1969-09-25 1975-03-04 Allied Chem Preparation of acid chlorides with phosgene in the presence of a catalyst
GB1456323A (en) * 1974-06-06 1976-11-24 Labaz Benzothiophenes process for preparing them and pharmaceutical compositions containing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
ZA822247B (en) 1981-04-03 1983-11-30 Lilly Co Eli Benzothiophene compounds and process for preparing them
PH18628A (en) 1981-04-03 1985-08-23 Lilly Co Eli "6-hydroxy-2-(4-hydroxyphenyl)-3 4-(2- piperidine or 3-methylpyrollidine -benzo b thiophene compounds
IL65378A (en) * 1981-04-03 1986-02-28 Lilly Co Eli Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4358593A (en) * 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
IL65379A0 (en) * 1981-04-03 1982-05-31 Lilly Co Eli Process for preparing acylated benzothiophenes
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5523416A (en) 1994-07-22 1996-06-04 Eli Lilly And Company Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes
CO4410191A1 (es) * 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS

Also Published As

Publication number Publication date
GB9519028D0 (en) 1995-11-15
DK175887B1 (da) 2005-05-23
CA2158399A1 (en) 1996-03-20
RS49513B (sr) 2006-10-27
YU61495A (sh) 1998-05-15
ES2129293A1 (es) 1999-06-01
CH691478A5 (de) 2001-07-31
PL182450B1 (pl) 2002-01-31
SK23397A3 (en) 1997-08-06
EE9700055A (et) 1997-08-15
PT101771B (pt) 1997-04-30
NO953658D0 (no) 1995-09-15
JPH08193081A (ja) 1996-07-30
NL1001194A1 (nl) 1996-03-19
NL1001196C2 (nl) 1997-04-04
SI9500292A (en) 1996-06-30
DE19534745A1 (de) 1996-04-04
LV11177A (lv) 1996-04-20
KR100381346B1 (ko) 2004-04-13
DE19534745B4 (de) 2004-06-09
DK102795A (da) 1996-03-20
GR1002709B (el) 1997-06-04
SI9500293A (en) 1996-06-30
GB2293602A (en) 1996-04-03
HUT75033A (en) 1997-03-28
PL310518A1 (en) 1996-04-01
NO953658L (no) 1996-03-20
CO4410190A1 (es) 1997-01-09
CN1075069C (zh) 2001-11-21
RS49578B (sr) 2007-04-10
SE9503213L (sv) 1996-03-20
PE14796A1 (es) 1996-05-19
UA42716C2 (uk) 2001-11-15
IL115314A0 (en) 1996-05-14
CA2158399C (en) 2001-03-20
ITMI951935A1 (it) 1997-03-15
NO953657L (no) 1996-03-20
JPH08176147A (ja) 1996-07-09
US20020173645A1 (en) 2002-11-21
YU61395A (sh) 1998-09-18
AU3173195A (en) 1996-04-04
LV11177B (en) 1996-08-20
DK175903B1 (da) 2005-06-06
AU3718695A (en) 1996-04-09
CH691125A5 (de) 2001-04-30
IL115314A (en) 2000-02-29
NZ280028A (en) 1997-05-26
GR1002697B (el) 1997-05-22
UA44240C2 (uk) 2002-02-15
LV11178A (lv) 1996-04-20
SE9503214D0 (sv) 1995-09-15
GB2293382B (en) 1998-08-19
TR199501136A2 (tr) 1996-06-21
CH691594A5 (de) 2001-08-31
ES2109882B1 (es) 1998-08-16
BE1009625A3 (fr) 1997-06-03
HRP950483B1 (en) 2003-02-28
DK175897B1 (da) 2005-05-30
AT502957A1 (de) 2007-06-15
BE1009626A3 (fr) 1997-06-03
BG62793B1 (bg) 2000-08-31
IT1277602B1 (it) 1997-11-11
IS1788B (is) 2001-11-28
DK2897A (da) 1997-01-09
CN1068324C (zh) 2001-07-11
PT101770B (pt) 1997-04-30
AU691955B2 (en) 1998-05-28
CO4410191A1 (es) 1997-01-09
IL115315A0 (en) 1995-12-31
GEP19991821B (en) 1999-11-05
CZ292007B6 (cs) 2003-07-16
NO953657D0 (no) 1995-09-15
CZ240295A3 (en) 1996-04-17
JP2860071B2 (ja) 1999-02-24
CA2158400C (en) 2006-10-24
KR100367376B1 (ko) 2003-03-06
CN1132205A (zh) 1996-10-02
AP9700938A0 (en) 1997-04-30
NL1001194C2 (nl) 1997-04-04
DK2797A (da) 1997-01-09
SE9503213D0 (sv) 1995-09-15
IT1277601B1 (it) 1997-11-11
KR960010634A (ko) 1996-04-20
FI954403A7 (fi) 1996-03-20
FR2724655A1 (fr) 1996-03-22
FI112226B (fi) 2003-11-14
PL187686B1 (pl) 2004-09-30
SE509265C2 (sv) 1998-12-21
BG101242A (en) 1998-03-31
IE950721A1 (en) 1996-03-20
NL1001196A1 (nl) 1996-03-19
HUT74178A (en) 1996-11-28
FI954403A0 (fi) 1995-09-18
FR2732020B1 (fr) 1997-11-14
DE19549755B4 (de) 2005-05-04
ES2109882A1 (es) 1998-01-16
HU227683B1 (en) 2011-11-28
LU88661A1 (fr) 1996-07-15
AT407988B (de) 2001-07-25
IE80883B1 (en) 1999-05-19
NZ280027A (en) 1997-05-26
SE9503214L (sv) 1996-03-20
UY24040A1 (es) 1996-03-07
ITMI951935A0 (it) 1995-09-15
IL125283A (en) 2001-06-14
OA10406A (en) 2001-12-05
TW412534B (en) 2000-11-21
CZ290343B6 (cs) 2002-07-17
US6472531B1 (en) 2002-10-29
ATA154295A (de) 2000-12-15
LU88660A1 (fr) 1996-07-15
HU9502723D0 (en) 1995-11-28
FR2732020A1 (fr) 1996-09-27
AP754A (en) 1999-07-22
CA2158400A1 (en) 1996-03-20
WO1996009045A1 (en) 1996-03-28
EG23763A (en) 2007-08-08
NO313996B1 (no) 2003-01-13
FI954402L (fi) 1996-03-20
DK175886B1 (da) 2005-05-23
FR2724655B1 (fr) 1997-11-14
BR9504060A (pt) 1996-09-24
HU9502721D0 (en) 1995-11-28
IS4446A (is) 1997-03-18
LV11178B (en) 1996-08-20
AU3173095A (en) 1996-04-04
EE03386B1 (et) 2001-04-16
IL115315A (en) 1999-09-22
HRP950483A2 (en) 1997-10-31
SE520721C2 (sv) 2003-08-12
GB2293602B (en) 1998-05-06
SK283502B6 (sk) 2003-08-05
MY116371A (en) 2004-01-31
RO115260B1 (ro) 1999-12-30
NO308107B1 (no) 2000-07-24
PL310517A1 (en) 1996-04-01
GB2293382A (en) 1996-03-27
HRP950482A2 (en) 1998-02-28
IE950722A1 (en) 1996-03-20
KR960010637A (ko) 1996-04-20
AU692907B2 (en) 1998-06-18
US5731327A (en) 1998-03-24
GB9519032D0 (en) 1995-11-15
HU225417B1 (en) 2006-11-28
HK1019009A1 (en) 2000-01-14
DE19534744A1 (de) 1996-03-21
ITMI951936A0 (it) 1995-09-15
PT101771A (pt) 1996-04-30
ITMI951936A1 (it) 1997-03-15
US6399778B1 (en) 2002-06-04
PT101770A (pt) 1996-04-30
ES2129293B1 (es) 2000-01-16
FI121424B (fi) 2010-11-15
DK102895A (da) 1996-03-20
RO115259B1 (ro) 1999-12-30
FI954402A0 (fi) 1995-09-18
CZ240395A3 (en) 1996-04-17
PE32796A1 (es) 1996-08-07
HRP950482B1 (en) 2007-04-30
CN1127253A (zh) 1996-07-24

Similar Documents

Publication Publication Date Title
BR9504059A (pt) Processo para a preparação de um solvato cristalino de um composto solvato cristalino processo para a preparação de hidrocloreto de 6-hidróxido-2-(4-hidroxifenil)-3-(4-(2-piperidinoetóxi)benzoil)benzo(B)tiofeno e o hidrocloreto obtido
NO970939D0 (no) Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat
PL300235A1 (en) 5-{2-[4-(1,2-benzoisothiazolyl-3)-1-piperozinyl] ethyl}-6-chloro-1,3-dihydro-2h-indolone-2 hydrochloride monohydrate
BR9605906A (pt) Compostos benzo-heterociclicos substituídos por aminoalquila utilizaçao processo para sua fabricaçao e agentes com açao antimicótica e redutora do colesterol contendo os mesmos
PT96617A (pt) Processo para a preparacao de agentes antifungicos de triazol
FI974363L (fi) 2-(1H-4(5)-imidatsoyyli)syklopropyylijohdannaiset
GB2246587B (en) Stripper rubbers for drilling heads
FI933599A7 (fi) Telekopiointitietojen menetysten minimointi solukkoverkon kanavanvaihd on aikana
ATE201872T1 (de) Kristallines hydrochlorid von (r)-(-)-2-(n-(4-(1, 1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl) butyl)-aminomethyl)-chroman
PT1068182E (pt) Processo para preparar uma 4-aminometilpirrolidin-3-ona protegida
BR9107205A (pt) Processo para a sintese de uma classe de compostos
ATE251151T1 (de) Eine kristalline form von 6-hydroxy-3-(4-(2- (piperidin-1-yl)ethoxy)phenoxy)-2-(4- methoxyphenyl)benzo(b)thiophen-hydrochlorid
PT94008A (pt) Processo para a preparacao de novos derivados de tieno-triazolo-diazepina
BR9608468A (pt) Processo para a preparação de n-metil-2-(3,4-dimetoxifenil)-etilamina
FI20001722A0 (fi) 6-hydroksi-3-(4-/2-(piperidin-1-yyli)etoksi/fenoksi)-2-(4-metoksifenyyli)bentso/b/tiofeenihydrokloridin uusi kiteinen muoto
FI883960L (fi) Menetelmä buspironihydrokloridin polymorfisen kiteisen muodon muuttamiseksi sen toiseksi kiteiseksi muodoksi
BR9711131A (pt) Processo para preparar um composto e compostos
NO20010629D0 (no) Fremgangsmåte for fremstilling av en ikke-krystallinsk anhydratform av paroksetinhydroklorid
IL155487A0 (en) A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2- (PIPERIDIN-1-YL) ETHOXY] PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
IT7928251A0 (it) Processo per la sintesi di 4-[2-(dimetilammino)-etossi]2-metil-5-81-metiletil)-fenol-este ri
CY2344B1 (en) A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
YU195589A (en) Process for obtaining 2-(diethylamino)-n-(2,6-dimethylphenyl) acetamide hydrochloride hydrate
IT1204336B (it) Processo per la preparazione di 2-(n-benzil-n-metilammino)-etil-metil1,4-diidro-2,6-dimetil-4-(3-nitrofenil)-3,5-piridin-dicarbossilato cloridrato
GR862182B (en) Method for preparing 1-((4-fluorophenyl) methyl)-n-(1-(2-(4-methoxyphenyl) ethyl-4-piperidinyl)-1h-benzimidazole-2-amine
NO893763D0 (no) Fremgangsmaate ved markering av et trafikkert underlag.

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/09/2015